PDF(Pubmed)
Abstract：
CEBPA variants are frequently recurring in acute myeloid leukemia (AML). The prognostic significance of CEBPA mutations has recently undergone a major shift in the 5th edition of WHO classification of hematological neoplasms and ELN 2022 classification. Whereas prior iterations did not specify the type of CEBPA mutation, the updated schema specify that only mutations localized to the C-terminal basic zipper (bZIP) domain are considered prognostically favorable. This change is based primarily on three recently published large datasets evaluating the prognostic significance of mutation location in CEBPA mutant AML. Here, we review the evolution of the prognostic classification of CEBPA variants.
摘要：
CEBPA变体经常在急性髓性白血病（AML）中复发。CEBPA突变的预后意义最近在第5版WHO血液肿瘤分类和ELN2022分类中发生了重大转变。以前的迭代没有指定CEBPA突变的类型，更新的模式指定只有位于C端基本拉链（bZIP）域的突变被认为在预后上是有利的。这种变化主要基于最近发表的三个大型数据集，这些数据集评估了CEBPA突变AML中突变位置的预后意义。这里,我们回顾了CEBPA变异体预后分类的演变过程.
